Met Life Investment Management, LLC Inozyme Pharma, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 23,958 shares of INZY stock, worth $28,749. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,958
Previous 27,949
14.28%
Holding current value
$28,749
Previous $146,000
54.79%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding INZY
# of Institutions
104Shares Held
50.7MCall Options Held
2.6KPut Options Held
5.1K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.16MShares$6.19 Million0.03% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$5.39 Million11.45% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$5.14 Million0.97% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.97MShares$4.77 Million1.97% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.86MShares$4.63 Million0.43% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $48.2M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...